Jubilant Pharmova Ltd
Jubilant Pharmova Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹1,929Cr
- +9.7% YoY
- Net profit
- ₹151Cr
- Q4 FY24: −₹62 Cr
- Margin
- 18%
- +3 pp YoY
Guidance rank: #70 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Jubilant Pharmova Ltd Q4 FY25 key numbers
- Revenue
- Some segments showed decline due to product focus, e.g., 22% decrease YoY to Rs. 157 Cr.
As stated in Jubilant Pharmova Ltd's Q4 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.
Based on Jubilant Pharmova Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY25 consolidated revenue grew 10% YoY to Rs. 1,929 Cr. Q4 FY25 EBITDA: Rs. 357 Cr., up 23% YoY.
From Jubilant Pharmova Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY25 consolidated revenue grew 10% YoY to Rs. 1,929 Cr.
- Full year FY25 revenue grew 8% YoY to Rs. 7,235 Cr.
- Specific segments:
- Revenue grew 31% YoY to Rs. 340 Cr. (Page 46)
- Revenue increased 33% YoY to Rs. 156 Cr. (Page 53)
- Revenue increased 11% YoY to Rs. 182 Cr. (Page 58)
- Revenue increased 2% YoY to Rs. 192 Cr. (Page 39)
- Some segments showed decline due to product focus, e.g., 22% decrease YoY to Rs. 157 Cr. (Page 64)
- Outlook for FY26: Continue revenue growth momentum and expand EBITDA margins (Page 94)
2 more points from Jubilant Pharmova Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Spokane, Washington, USA expansion: Lines 3 & 4, total investment USD 285 million (RoCE > 20%) including USD 150 million US Govt. funding. Line 3 media-fill and product qualification completed; commercial production expected to start FY26. Revenue potential USD 160-180 million. Full capacity utilization expected in 3 years (vs 4 years earlier).
- Current sites Greater Noida & Bengaluru: Expansion ongoing with capacity 1,000 FTEs FY25, 2,000 FTEs FY26, 4,000 FTEs FY27. Total capex USD 150 million, expected RoCE > 20%.
- PET radiopharmaceuticals expansion: Fully operational by FY28 with funding from internal accruals and long-term credit; USD 50 million investment targeting asset turnover 1.0x and RoCE > 20%.
2 more points from Jubilant Pharmova Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Jubilant Pharmova Ltd said on order book & pipeline — free account, 30 seconds.
Jubilant Pharmova Ltd — Quarterly revenue & net profit
Jubilant Pharmova Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,929 | 1,759 | +9.7% | 1,822 | +5.9% |
| Operating profit (EBITDA) | 345 | 271 | +27.3% | 287 | +20.2% |
| Operating margin | 18% | 15% | +3 pp | 16% | +2 pp |
| Profit before tax | 206 | -54 | — | 130 | +58.5% |
| Net profit (PAT) | 151 | -62 | — | 101 | +49.5% |
| EPS (₹) | 9.64 | -3.68 | — | 6.33 | +52.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.3K Cr, net profit ₹119 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Pharmo's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Anuh Pharma (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
- Kopran (Q4 FY25)
1,372 Lakhs (~7.37% decline) . Key concall takeaways from Kopran Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jubilant Pharmova Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jubilant Pharmova Ltd Q4 FY25 results?
Q4 FY25 consolidated revenue grew 10% YoY to Rs. 1,929 Cr. Q4 FY25 EBITDA: Rs. 357 Cr., up 23% YoY.
What is Jubilant Pharmova Ltd share price analysis?
Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Pharmova Ltd planning capital expenditure?
Spokane, Washington, USA expansion: Lines 3 & 4, total investment USD 285 million (RoCE > 20%) including USD 150 million US Govt.
Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.